Lantern Pharma Fails Nasdaq Listing Rule

Lantern Pharma received notice from Nasdaq on September 25, 2026, that it failed to meet Listing Rule 5550(b)(2) due to its market value of listed securities being below $35 million for 30 consecutive business days. It also does not meet rules 5550(b)(1) and 5550(b)(3). The company has 180 days until March 24 to regain compliance.